Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

GTXI Q2 Loss Widens

RELATED NEWS
Trade GTXI now with 

GTX Inc. (GTXI: Quote) reported that its second-quarter net loss was $12.8 million or $0.20 per share, compared to a net loss of $10.4 million or $0.17 per share for the same period in 2012. Analysts polled by Thomson Reuters expected the company to report a loss of $0.22 per share for the quarter. Analysts' estimates typically exclude special items.

The company's net loss for the second quarter of 2012 was reduced by net income from discontinued operations of $848,000 related to sales of the commercial product FARESTON®, the rights for which the Company sold in the third quarter of 2012.

Research and development expenses for the quarter were $10.1 million compared to $9.2 million for the same period of 2012. General and administrative expenses for the quarter ended were $2.7 million compared to $2.4 million for the same period of 2012.

GTx said it is evaluating enobosarm (GTx-024) 3 mg, an oral selective androgen receptor modulator, for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer in two pivotal Phase 3 clinical trials. The last patients completed these clinical trials during May 2013. Vital status (survival) of patients participating in the studies will continue to be periodically monitored in accordance with the clinical trial protocols.

The company anticipates providing the topline results for both studies later this quarter which will include the coprimary endpoints, safety assessments, and an update on survival.

GTx noted that it continues to enroll the Phase 2, open label clinical trial evaluating enobosarm 9 mg for the treatment of androgen receptor positive and estrogen receptor positive metastatic breast cancer in women who have previously responded to hormonal therapy for the treatment of their advanced breast cancer, which was initiated in the second quarter of 2013. Additionally, GTx continues the enrollment of the Phase 2 clinical trial evaluating Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer.

Register
To receive FREE breaking news email alerts for GTX Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
U.S. astronauts once again will travel to and from the International Space Station from the United States on American spacecraft under groundbreaking contracts NASA announced Tuesday. The US space agency unveiled its selection of Boeing and SpaceX to transport U.S. crews to and from the space station using their CST-100 and Crew Dragon spacecraft, respectively. "From day one, the Obama Administra China's central bank is providing stimulus to the country's largest lenders to boost liquidity amid slowing growth, media reports said Wednesday, citing government and banking sources. The People's Bank of China is injecting CNY 500 billion or $81 billion for a three-month period into the top five... Europe's passenger car registrations continued to rise in August, pursuing the upward trend commenced twelve months ago, the European Automobile Manufacturers Association reported Wednesday. Car sales increased 2.1 percent in August and 5.6 percent in July. Overall, 688,464 new cars were registered...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.